Charles River Laboratories International (CRL) Fundamental Analysis: Revenue, Earnings & Valuation

0.62 / 10

Underperform

Fundamentals rate Underperform with a 0.6/10 score. Inventory turnover days and net‑income‑to‑revenue are strengths, while total‑asset turnover and cost‑of‑sales ratio lag. Overall, the company’s financial health is weak, warranting a guarded view.

Analysis Checks(3/10)

Profit-MV

Value0.68

Score1/3

Weight5.28%

1M Return-0.79%

Net income-Revenue

Value-0.04

Score2/3

Weight1.54%

1M Return-0.22%

PB-ROE

Value0.31

Score1/3

Weight1.45%

1M Return-0.23%

Current assets turnover ratio

Value2.82

Score3/3

Weight-15.43%

1M Return2.34%

Cash-UP

Value-0.50

Score1/3

Weight29.17%

1M Return-6.72%

Total assets turnover ratio

Value0.55

Score1/3

Weight5.85%

1M Return-0.89%

Cost of sales ratio (%)

Value67.04

Score0/3

Weight39.54%

1M Return-7.50%

Asset-MV

Value-0.55

Score0/3

Weight22.90%

1M Return-7.15%

Inventory turnover days

Value38.62

Score3/3

Weight-14.96%

1M Return2.26%

Cash-MV

Value-0.44

Score1/3

Weight24.67%

1M Return-3.18%

Is CRL fundamentally strong?

CRL scores 0.62/10 on fundamentals and holds a Premium valuation at present. Backed by its -4.30% ROE, -3.54% net margin, -54.28 P/E ratio, 2.44 P/B ratio, and -1555.00% earnings growth, these metrics solidify its Underperform investment rating.